Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,572,834

« Back to Dashboard
Patent 7,572,834 protects AZILECT and is included in one NDA. There has been one Paragraph IV challenge on Azilect. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Summary for Patent: 7,572,834

Title:Rasagiline formulations and processes for their preparation
Abstract:The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: ##STR00001## and any salts of the compound.
Inventor(s): Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Rosen; Harel (Ra'anana, IL), Bronov; Leonid (Netanya, IL), Medini-Green; Dalia (Pardes Hanna, IL), Iosefzon; Berta (Jerusalem, IL), Berger-Peskin; Tirtsah (Ra'anana, IL), Lidor-Hadas; Ramy (Kfar Saba, IL), Bahar; Eliezer (Tel Aviv, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL)
Application Number:11/634,916
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 34th percentile
Forward Citations: 10th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006RXYesNo7,572,834► subscribeY
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006RXYesYes7,572,834► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,572,834

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,619,117Rasagiline formulations and processes for their preparation► subscribe
7,598,420Rasagiline formulations and processes for their preparation► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.